JP2020171316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020171316A5 JP2020171316A5 JP2020120557A JP2020120557A JP2020171316A5 JP 2020171316 A5 JP2020171316 A5 JP 2020171316A5 JP 2020120557 A JP2020120557 A JP 2020120557A JP 2020120557 A JP2020120557 A JP 2020120557A JP 2020171316 A5 JP2020171316 A5 JP 2020171316A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- disease
- dermatomyositis
- composition
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 201000001981 dermatomyositis Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 7
- 230000004927 fusion Effects 0.000 claims 7
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000005987 polymyositis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000036541 health Effects 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 108010091326 Cryoglobulins Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010058461 Orchitis noninfective Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 1
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 claims 1
- 229950010333 exalamide Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 230000003862 health status Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 238000002278 reconstructive surgery Methods 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 239000003001 serine protease inhibitor Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500795P | 2011-06-24 | 2011-06-24 | |
| US61/500,795 | 2011-06-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019012303A Division JP2019058197A (ja) | 2011-06-24 | 2019-01-28 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020171316A JP2020171316A (ja) | 2020-10-22 |
| JP2020171316A5 true JP2020171316A5 (enExample) | 2021-06-10 |
Family
ID=47423247
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517226A Expired - Fee Related JP6216921B2 (ja) | 2011-06-24 | 2012-06-22 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2016246746A Withdrawn JP2017079769A (ja) | 2011-06-24 | 2016-12-20 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2019012303A Pending JP2019058197A (ja) | 2011-06-24 | 2019-01-28 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2020120557A Pending JP2020171316A (ja) | 2011-06-24 | 2020-07-14 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517226A Expired - Fee Related JP6216921B2 (ja) | 2011-06-24 | 2012-06-22 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2016246746A Withdrawn JP2017079769A (ja) | 2011-06-24 | 2016-12-20 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2019012303A Pending JP2019058197A (ja) | 2011-06-24 | 2019-01-28 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9938353B2 (enExample) |
| EP (2) | EP3628327A1 (enExample) |
| JP (4) | JP6216921B2 (enExample) |
| KR (2) | KR20200044138A (enExample) |
| AU (4) | AU2012272636A1 (enExample) |
| CA (1) | CA2839917A1 (enExample) |
| WO (1) | WO2012178102A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2520654T3 (en) | 2003-08-26 | 2017-05-01 | Univ Colorado Regents | Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections |
| EP3628327A1 (en) * | 2011-06-24 | 2020-04-01 | The Regents of the University of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| SMT201900520T1 (it) * | 2011-06-28 | 2019-11-13 | Inhibrx Lp | Polipeptidi di fusione serpinici e relativi metodi d'uso |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| KR20140137347A (ko) * | 2012-01-10 | 2014-12-02 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
| CA2943938A1 (en) | 2013-03-29 | 2014-10-02 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for preparing a subject for organ or non-organ implantation |
| CN105431165A (zh) | 2013-05-15 | 2016-03-23 | 莫尔研究应用有限公司 | 用于治疗心肺手术后的术后并发症的组合物和方法 |
| EP4219534A3 (en) | 2013-07-08 | 2023-09-27 | The University of Utah Research Foundation | Methods for treatment of and prophylaxis against inflammatory disorders |
| JP6372562B2 (ja) * | 2014-03-19 | 2018-08-15 | 株式会社安川電機 | 回転電機 |
| US20170190762A1 (en) * | 2014-06-11 | 2017-07-06 | Beth Israel Deaconess Medical Center, Inc. | Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases |
| WO2016144984A1 (en) * | 2015-03-10 | 2016-09-15 | Anvil Biosciences, Llc | Serpins for the treatment of neuroinflammatory diseases |
| CA3054267A1 (en) * | 2017-02-21 | 2018-08-30 | Kamada Ltd. | Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases |
| ES3059603T3 (en) * | 2017-12-01 | 2026-03-23 | Csl Behring Llc | A1at for treating acute graft versus host disease after hematopoeitic cell transplantation |
| EP3802587A4 (en) * | 2018-06-07 | 2022-03-23 | Prottech Inc. | PHARMACEUTICAL COMPOSITION WITH A FUSION PROTEIN AND THEIR USE |
| CN109251936B (zh) * | 2018-09-20 | 2021-09-10 | 四川理工学院 | 一种光滑鳖甲丝氨酸蛋白酶抑制剂融合蛋白及制备与应用 |
| US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| KR20220133227A (ko) * | 2020-01-30 | 2022-10-04 | 버텍스 파마슈티칼스 인코포레이티드 | 알파-1 항트립신 결핍증의 치료 방법 |
| WO2021178448A1 (en) * | 2020-03-02 | 2021-09-10 | Motor Life Sciences, Llc | Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity |
| AU2021247285A1 (en) | 2020-04-03 | 2022-10-27 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| JP7732999B2 (ja) | 2020-04-03 | 2025-09-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | アルファ１－アンチトリプシンのモジュレーター |
| CN115697969B (zh) | 2020-04-03 | 2026-08-11 | 弗特克斯药品有限公司 | α-1抗胰蛋白酶调节剂 |
| EP4188931A2 (en) | 2020-07-27 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Processes for preparing modulators of alpha-1 antitrypsin |
| KR102689456B1 (ko) * | 2020-11-16 | 2024-07-29 | 경북대학교 산학협력단 | 알파-1 안티트립신을 포함하는 면역억제제에 의한 신장손상 예방 또는 치료용 조성물 |
| EP4507720A1 (en) * | 2022-04-14 | 2025-02-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections |
| EP4480493A1 (en) * | 2023-06-22 | 2024-12-25 | AATEC Medical GmbH | A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung |
| EP4730999A1 (en) * | 2023-06-22 | 2026-04-29 | AATEC Medical GmbH | Recombinant aat from yeast to treat transplants |
| EP4743578A2 (en) * | 2023-07-10 | 2026-05-20 | Precigen, Inc. | THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY |
| KR20250076724A (ko) * | 2023-11-22 | 2025-05-30 | 아주대학교산학협력단 | 지속형 재조합 알파-1 항트립신 및 이의 용도 |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| GB1472700A (en) | 1974-11-01 | 1977-05-04 | Ono Pharmaceutical Co | Guanidinobehzoic acid derivatives and process for preparing the same |
| JPS5470241A (en) | 1977-11-09 | 1979-06-05 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivative and its preparation |
| GB2044760B (en) | 1979-03-01 | 1983-03-23 | Ono Pharmaceutical Co | Guanidinobenzoic acid derivatives |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| AU577259B2 (en) | 1982-08-13 | 1988-09-22 | Zymogenetics Inc. | Glycolytic promters for regulated protein expression protease inhibitor |
| US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
| JP2599585B2 (ja) | 1984-06-19 | 1997-04-09 | トランスジ−ン ソシエテ アノニム | ヒトα▲下１▼−アンチトリプシン誘導体及びその製造法 |
| US4629567A (en) | 1986-03-07 | 1986-12-16 | Smithkline-Rit | Alpha-1-antiprotease purification |
| US5157019A (en) | 1986-03-18 | 1992-10-20 | Monsanto Company | Serine protease inhibitors |
| US4829052A (en) | 1986-06-11 | 1989-05-09 | Monsanto Company | Serine protease inhibitors |
| US5093316A (en) | 1986-12-24 | 1992-03-03 | John Lezdey | Treatment of inflammation |
| US5008242A (en) | 1986-12-24 | 1991-04-16 | John Lezdey | Treatment of inflammation using 1-antichymotrypsin |
| US4829054A (en) | 1987-04-13 | 1989-05-09 | Miles Laboratories, Inc. | Method of decreasing lung damage in a host following the onset of gram negative septicemia/endotoxemia |
| US4857538A (en) | 1987-11-30 | 1989-08-15 | The Research Foundation Of State University Of New York | New compounds for the study and treatment of microfilament organization in cells |
| US4963654A (en) | 1989-02-13 | 1990-10-16 | Taisho Pharmaceutical Co., Ltd. | Peptide serine protease inhibitor |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| GB8909916D0 (en) | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
| US5612194A (en) | 1989-06-23 | 1997-03-18 | Trustees Of The University Of Pennsylvania | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors |
| JP2568281B2 (ja) | 1989-11-17 | 1996-12-25 | 原田工業株式会社 | 自動車用三波共用アンテナ |
| US5714140A (en) | 1989-12-13 | 1998-02-03 | Otsuka Pharmaceutical Co., Ltd. | Method for inhibiting the production of bioactive IL-1 by administering M-CSF |
| US5134119A (en) | 1990-10-16 | 1992-07-28 | Lezdey John | Treatment of inflammation using 358 substituted alpha-antitrypsin |
| ATE146970T1 (de) | 1990-10-16 | 1997-01-15 | John Lezdey | Behandlung von entzündungen |
| US5470970A (en) | 1991-02-28 | 1995-11-28 | Dana-Farber Cancer Institute, Inc. | Maspin, a serpin with tumor suppresing activity |
| EP0616614A1 (en) | 1991-04-18 | 1994-09-28 | The Uab Research Foundation | Compositions and methods for inhibiting elastase |
| US5175253A (en) | 1991-04-24 | 1992-12-29 | Washington University | Binding peptides |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| US5216022A (en) | 1991-12-19 | 1993-06-01 | Cortech, Inc. | Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase |
| AU3968193A (en) | 1992-03-26 | 1993-10-21 | Gensia, Inc. | In vivo peptide therapy |
| GB9209032D0 (en) * | 1992-04-25 | 1992-06-10 | Ciba Geigy Ag | New peptide derivatives |
| US5734014A (en) | 1992-08-11 | 1998-03-31 | Tsumura & Co. | Elafin derivative |
| US5376633A (en) | 1992-09-30 | 1994-12-27 | Lezdey; John | Method for deactivating viruses in blood component containers |
| US5604201A (en) | 1993-01-08 | 1997-02-18 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization | Methods and reagents for inhibiting furin endoprotease |
| US5346886A (en) | 1993-11-15 | 1994-09-13 | John Lezdey | Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin |
| JPH0827371A (ja) | 1994-05-09 | 1996-01-30 | Japan Carlit Co Ltd:The | 紫外線及び赤外線吸収樹脂組成物 |
| EP0764151A2 (en) | 1994-06-10 | 1997-03-26 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
| US5610285A (en) | 1994-08-24 | 1997-03-11 | Bayer Corporation | Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions |
| US5514653A (en) | 1994-09-09 | 1996-05-07 | Washington University | Method of blocking the SEC receptor |
| US5618792A (en) | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
| US5712117A (en) | 1995-02-08 | 1998-01-27 | Zymogenetics, Inc. | Cytoplasmic antiproteinase-2 and coding sequences |
| EP0910564B1 (en) | 1995-11-28 | 2007-10-31 | Cephalon, Inc. | D-amino acid derived inhibitors of cysteine and serine proteases |
| WO1997024339A1 (en) | 1995-12-27 | 1997-07-10 | Ono Pharmaceutical Co., Ltd. | Tetrazole derivatives and drugs containing the same as the active ingredient |
| WO1997033996A2 (en) | 1996-03-11 | 1997-09-18 | Bayer Corporation | Human bikunin |
| US6072041A (en) | 1996-06-03 | 2000-06-06 | Case Western Reserve University | Fusion proteins for protein delivery |
| US5780440A (en) | 1996-06-17 | 1998-07-14 | Protease Sciences Inc. | Treatment of pulmonary disease with protease inhibitors |
| US5616693A (en) | 1996-07-01 | 1997-04-01 | Alpha Therapeutic Corporation | Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| ES2293661T3 (es) | 1996-11-27 | 2008-03-16 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteinas a. |
| TR199901681T2 (xx) | 1996-12-06 | 2000-03-21 | Cortech, Inc. | Serin proteas inhibit�rleri. |
| US6150332A (en) * | 1997-01-09 | 2000-11-21 | Virginia Commonwealth University | Method and composition for lowering low density lipoprotein cholesterol |
| US6127145A (en) | 1997-02-13 | 2000-10-03 | Applied Phytologics, Inc. | Production of α1 -antitrypsin in plants |
| US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| DE19735587B4 (de) | 1997-08-16 | 2012-03-22 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens |
| US6124257A (en) | 1997-08-28 | 2000-09-26 | Lezdey; John | Method of treatment |
| US6964869B2 (en) | 1998-07-13 | 2005-11-15 | Wisconsin Alumni Research Foundation | Method and composition for skin grafts |
| WO2002053092A2 (en) | 2001-01-04 | 2002-07-11 | Vascular Biogenics Ltd. | Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| US6197294B1 (en) | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
| WO2000044390A1 (en) | 1999-02-01 | 2000-08-03 | John Lezdey | Treatment of bladder and gastrointestinal mastocytosis |
| GB9904421D0 (en) | 1999-02-25 | 1999-04-21 | Univ Edinburgh | Telecommunications receiver |
| JP2002537810A (ja) * | 1999-03-01 | 2002-11-12 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒトセルピンタンパク質 |
| WO2000052034A2 (en) | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
| US6849605B1 (en) | 1999-03-05 | 2005-02-01 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
| AU3731400A (en) | 1999-03-05 | 2000-09-21 | Trustees Of University Technology Corporation, The | Methods and compositions useful in inhibiting apoptosis |
| AU3864000A (en) | 1999-03-05 | 2000-09-21 | Trustees Of University Technology Corporation, The | Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses |
| WO2000051623A2 (en) | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
| US6174859B1 (en) | 1999-04-06 | 2001-01-16 | J & D Sciences, Inc. | Method of treatment |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| EP1231936A2 (en) | 1999-10-27 | 2002-08-21 | K-Quay Enterprises, LLC | Methods and compositions for treatment of keratoconus using protease inhibitors |
| JP2003515325A (ja) | 1999-12-01 | 2003-05-07 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４ジスルフィドコアドメイン含有（ｆｄｃｄ）ポリヌクレオチド、ポリペプチド、および抗体 |
| US6955845B1 (en) | 2000-06-30 | 2005-10-18 | Owens Corning Fiberglas Technology, Inc. | Acoustical and thermal insulator |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7247704B2 (en) | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
| EE200300408A (et) | 2001-02-23 | 2003-12-15 | Immunex Corporation | Aktiivsete valkude saagise suurendamine |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2002094986A2 (en) | 2001-05-21 | 2002-11-28 | Board Of Reagents | Next-nearest-neighbor sequence determinants of antisense dna |
| ATE390931T1 (de) | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| WO2002094864A2 (en) | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
| US7001884B2 (en) | 2001-06-18 | 2006-02-21 | Regents Of The University Of Michigan | Eglin c based drugs for treatment of disease |
| AU2002317940B9 (en) | 2001-06-22 | 2008-06-05 | The Secretary Of State For Health | Mycobacterial antigens expressed under low oxygen tension |
| US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| US6924267B2 (en) | 2001-09-18 | 2005-08-02 | Suomen Punainen Risti Veripalvelu | Methods and active substances for protecting organs |
| US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| JP4363986B2 (ja) | 2001-12-21 | 2009-11-11 | イミュネックス・コーポレーション | タンパク質の精製方法 |
| CA2475388A1 (en) | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
| PT1551834E (pt) | 2002-05-23 | 2010-09-30 | Novartis Vaccines & Diagnostic | Compostos de quinazolinona substituídos |
| WO2004010989A1 (en) | 2002-07-25 | 2004-02-05 | Advances Life Sciences, Inc. | Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals |
| WO2004052236A2 (en) | 2002-12-06 | 2004-06-24 | Arriva Pharmaceuticals, Inc. | Methods and compositions for treatment of otitis media |
| US20040220242A1 (en) | 2003-05-02 | 2004-11-04 | Leland Shapiro | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions |
| DK2520654T3 (en) | 2003-08-26 | 2017-05-01 | Univ Colorado Regents | Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections |
| US20070238655A1 (en) | 2003-11-12 | 2007-10-11 | The Trustees Of The University Of Pennsylvania | Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis |
| BRPI0406605B8 (pt) * | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| CN1980694B (zh) | 2004-05-12 | 2012-09-26 | 布赖汉姆妇女医院有限公司 | 凝溶胶蛋白治疗感染的用途 |
| US8715649B2 (en) | 2005-06-07 | 2014-05-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
| WO2009005877A2 (en) | 2007-04-20 | 2009-01-08 | Regents Of The University Of Colorado | Alpha-i antitrypsin having no significant serine protease inhibitor activity |
| CA2654446C (en) * | 2005-06-07 | 2014-02-25 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
| US20090227518A1 (en) | 2005-12-02 | 2009-09-10 | The Regents Of The University Of Colorado | Compositions and methods for treating actin-mediated medical conditions |
| US20070280922A1 (en) | 2006-06-06 | 2007-12-06 | Zoltan Kiss Consulting | Combinations of human proteins to enhance viability of stem cells and progenitor cells |
| ES2651268T3 (es) | 2006-09-12 | 2018-01-25 | Beth Israel Deaconess Medical Center, Inc. | Composiciones que contienen alfa-1-antitripsina y métodos para su uso |
| PE20081250A1 (es) | 2006-11-28 | 2008-10-07 | Centelion | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA |
| WO2008100470A2 (en) | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
| WO2008138017A2 (en) * | 2007-05-08 | 2008-11-13 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| US20110077383A1 (en) | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
| WO2009015345A1 (en) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| US8067548B2 (en) | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| KR100992526B1 (ko) * | 2007-11-21 | 2010-11-05 | 한국과학기술연구원 | 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법 |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| CN102439044B (zh) | 2009-04-22 | 2014-08-13 | 阿特根公司 | 通过体内持续释放维持的体内半衰期增加的融合蛋白质或融合肽以及使用所述融合蛋白质或融合肽增加体内半衰期的方法 |
| WO2011102845A1 (en) | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
| US9522179B2 (en) | 2010-03-04 | 2016-12-20 | Virginia Commonwealth University | Compositions and methods for modulating cardiac conditions |
| WO2011156820A2 (en) | 2010-06-11 | 2011-12-15 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for treatment of type 1 diabetes |
| EP3628327A1 (en) | 2011-06-24 | 2020-04-01 | The Regents of the University of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| SMT201900520T1 (it) | 2011-06-28 | 2019-11-13 | Inhibrx Lp | Polipeptidi di fusione serpinici e relativi metodi d'uso |
| RU2639526C2 (ru) | 2011-06-28 | 2017-12-21 | ИНХИБРКС ЭлЭлСи | Слитые полипептиды, содержащие домен wap, и способы их применения |
| KR20140137347A (ko) | 2012-01-10 | 2014-12-02 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
-
2012
- 2012-06-22 EP EP19202264.8A patent/EP3628327A1/en not_active Withdrawn
- 2012-06-22 KR KR1020207011059A patent/KR20200044138A/ko not_active Ceased
- 2012-06-22 CA CA2839917A patent/CA2839917A1/en not_active Abandoned
- 2012-06-22 US US14/125,135 patent/US9938353B2/en active Active
- 2012-06-22 JP JP2014517226A patent/JP6216921B2/ja not_active Expired - Fee Related
- 2012-06-22 AU AU2012272636A patent/AU2012272636A1/en not_active Abandoned
- 2012-06-22 WO PCT/US2012/043869 patent/WO2012178102A2/en not_active Ceased
- 2012-06-22 KR KR1020147001915A patent/KR102103476B1/ko active Active
- 2012-06-22 EP EP12802540.0A patent/EP2723370A4/en not_active Ceased
-
2016
- 2016-04-28 AU AU2016202734A patent/AU2016202734A1/en not_active Abandoned
- 2016-12-20 JP JP2016246746A patent/JP2017079769A/ja not_active Withdrawn
-
2018
- 2018-01-24 AU AU2018200571A patent/AU2018200571C1/en not_active Ceased
- 2018-03-14 US US15/921,469 patent/US10450384B2/en active Active
-
2019
- 2019-01-28 JP JP2019012303A patent/JP2019058197A/ja active Pending
- 2019-09-16 US US16/572,371 patent/US20200109215A1/en not_active Abandoned
- 2019-10-29 AU AU2019257412A patent/AU2019257412B2/en not_active Ceased
-
2020
- 2020-07-14 JP JP2020120557A patent/JP2020171316A/ja active Pending
-
2021
- 2021-09-10 US US17/471,466 patent/US12030958B2/en active Active
-
2024
- 2024-05-07 US US18/656,832 patent/US20250101131A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019058197A5 (enExample) | ||
| EP4051265B1 (en) | Functionalized peptides containing two pyrrolidine rings as anticoronavirus agents | |
| AU2023266363B2 (en) | MASP-2 inhibitors and methods of use | |
| JP2007515432A5 (enExample) | ||
| AU2020244580B2 (en) | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same | |
| JP2017510575A5 (enExample) | ||
| JP2021507690A5 (enExample) | ||
| RU2010107994A (ru) | Композиции и способы кристаллизации антител | |
| RU2007142444A (ru) | Улучшенные нанотела против фактора некроза опухоли-альфа | |
| JP2022507741A5 (enExample) | ||
| JP2009534421A5 (enExample) | ||
| JP2010065035A5 (enExample) | ||
| JP2011528332A5 (enExample) | ||
| RU2016140572A (ru) | Конъюгаты антитело-финомер | |
| JP2020521458A5 (enExample) | ||
| JP2018525379A5 (enExample) | ||
| JP2014511844A5 (enExample) | ||
| JP2007514754A5 (enExample) | ||
| CA3258002A1 (en) | FCRN BINDING MOLECULES AND METHODS OF USE | |
| JP2014519852A5 (enExample) | ||
| RU2017118325A (ru) | Слитые серпиновые полипептиды и способы их применения | |
| JP2017537888A5 (enExample) | ||
| JP2011518857A5 (enExample) | ||
| RU2016133720A (ru) | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека | |
| JP2021073256A5 (enExample) |